Literature DB >> 3137026

Reversal of flunitrazepam with flumazenil: duration of antagonist activity.

M A Claeys1, F Camu, I Schneider, E Gepts.   

Abstract

The duration of action, dose requirements and efficacy of flumazenil, a specific benzodiazepine antagonist, were evaluated in 50 patients scheduled for orthopaedic surgery under local anaesthesia and flunitrazepam sedation. Fifteen minutes after injection of flunitrazepam 0.03 mg kg-1 the patients received placebo or flumazenil i.v. in a randomized, double-blind and titrated fashion. At selected time intervals, sedation, anterograde amnesia, muscular hypotonia, orientation in time and space, comprehension and collaboration were evaluated. Compared with placebo, flumazenil promptly reversed sedation for 30 min, hypotonia for 45 min and anterograde amnesia for 60 min, and improved orientation and collaboration for 60 min. However, after 90 min significant recurrent sedation was observed, while anterograde amnesia reappeared after 60 and up to 120 min. No side-effects were noted at any time. The dose of flumazenil required for reversal of flunitrazepam sedation was 0.35 +/- 0.15 mg (mean +/- SD).

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3137026

Source DB:  PubMed          Journal:  Eur J Anaesthesiol Suppl        ISSN: 0952-1941


  2 in total

Review 1.  Flumazenil. A reappraisal of its pharmacological properties and therapeutic efficacy as a benzodiazepine antagonist.

Authors:  R N Brogden; K L Goa
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

Review 2.  Flumazenil in dentistry.

Authors:  C Rodrigo
Journal:  Anesth Prog       Date:  1995
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.